commun
acquir
pneumonia
oseltamivir
viral
pneumonia
influenza
viral
swab
test
background
test
virus
patient
commun
acquir
pneumonia
cap
preval
risk
factor
viral
cap
still
debat
evalu
frequenc
viral
test
viru
preval
risk
factor
treatment
coverag
oseltamivir
patient
admit
cap
method
secondari
analysi
glimp
intern
multicent
pointpreval
studi
hospit
adult
cap
test
frequenc
preval
viral
cap
treatment
oseltamivir
assess
among
patient
underw
viral
swab
univari
multivari
analysi
use
evalu
risk
factor
result
patient
cap
underw
nasal
swab
viral
cap
diagnos
patient
influenza
viru
isol
case
test
frequenc
viral
cap
preval
inhomogen
across
particip
center
obes
ci
p
need
invas
mechan
ventil
ci
p
independ
associ
viral
cap
preval
empir
treatment
oseltamivir
conclus
intern
scenario
test
frequenc
virus
cap
low
common
caus
viral
cap
influenza
viru
obes
need
invas
ventil
repres
independ
risk
factor
viral
cap
adher
recommend
treatment
oseltamivir
poor
commun
acquir
pneumonia
cap
frequent
infecti
diseas
lower
respiratori
tract
repres
major
clinic
burden
worldwid
world
health
organ
estim
report
million
case
annual
furthermor
repres
substanti
cost
healthcar
system
eg
billion
dollar
unit
state
cap
caus
differ
microorgan
recent
virus
identifi
import
etiolog
pathogen
cap
patient
incid
viral
cap
high
major
impact
mortal
worldwid
especi
develop
countri
moreov
hospit
patient
viral
cap
requir
admiss
intens
care
unit
icu
preval
virus
caus
cap
might
underestim
clinic
practic
new
molecular
test
identifi
viral
pathogen
wide
avail
clinic
practic
clinic
present
bacteri
viral
pneumonia
may
overlap
consensu
exist
test
treat
viral
cap
differ
report
shown
preval
wide
vari
differ
term
studi
design
diagnost
techniqu
studi
popul
notabl
previou
experi
mainli
monocentr
limit
countri
repres
data
outsid
europ
north
america
importantli
viral
caprel
risk
factor
differ
studi
studi
final
current
avail
data
show
influenza
viru
preval
caus
viral
cap
oseltamivir
suggest
standard
care
evalu
global
preval
risk
factor
associ
viral
cap
necessari
help
decisionmak
process
primari
aim
present
studi
investig
frequenc
test
virus
preval
viral
cap
intern
level
secondari
aim
describ
popul
patient
viral
cap
evalu
oseltamivir
use
pragmat
point
preval
studi
present
studi
secondari
analysi
databas
collect
glimp
studi
intern
multicent
pointpreval
studi
hospit
adult
patient
diagnosi
cap
detail
methodolog
glimp
studi
publish
elsewher
studi
conduct
accord
amend
declar
helsinki
approv
institut
review
board
irb
univers
texa
health
scienc
center
san
antonio
tx
usa
particip
center
requir
compli
local
region
nation
research
regul
particip
studi
adult
year
old
hospit
cap
screen
studi
inclus
studi
sampl
includ
patient
underw
viral
nasopharyng
oropharyng
swab
first
h
patient
hospit
diagnosi
hospitalacquir
andor
ventilatorassoci
pneumonia
exclud
studi
studi
particip
enrol
singl
day
month
march
april
may
june
follow
variabl
collect
age
height
weight
gender
job
smoke
histori
pharmacolog
therapi
vaccin
statu
drug
alcohol
abus
oncolog
cardiovascular
respiratori
hepat
renal
comorbid
previou
healthcar
exposur
ie
emerg
room
admiss
intraven
oral
antibiot
hospit
lower
respiratori
tract
infect
previou
month
sever
diseas
first
h
hospit
admiss
prior
infect
colonis
multidrug
resist
pathogen
detail
list
characterist
risk
factor
evalu
pleas
see
appendix
patient
care
workup
might
includ
follow
specimen
blood
sampl
acutephas
serum
specimen
urin
sampl
nasopharyng
swab
sputum
case
product
cough
pleural
fluid
endotrach
aspir
bronchoalveolar
lavag
sampl
microbiolog
test
perform
first
h
admitt
hospit
consid
analysi
antimicrobi
antivir
antifung
treatment
administ
within
h
admiss
record
data
collect
manag
use
ad
hoc
report
form
dedic
data
captur
tool
patient
clinic
manag
collect
microbiolog
sampl
depend
attend
physician
per
studi
protocol
microbiolog
examin
perform
accord
local
standard
protocol
upper
airway
specimen
obtain
nasopharyng
oropharyng
swab
detect
follow
virus
adenoviru
coronaviru
human
metapneumoviru
hmpv
human
rhinoviru
influenza
viru
respiratori
syncyti
viru
rsv
test
viru
detect
carri
polymeras
chain
reaction
nucleic
acid
amplif
test
revers
transcriptas
polymeras
chain
reaction
rtpcr
rapid
influenza
diagnost
test
ridt
accord
local
standard
protocol
classif
viral
type
subtyp
perform
base
specif
sensit
nasopharyng
oropharyng
swab
specimen
consid
valid
viru
detect
microbiolog
test
bacteria
fungi
perform
accord
standard
local
protocol
follow
blood
upper
lower
tract
respiratori
cultur
eg
sputum
pleural
fluid
endotrach
aspir
bronchoalveolar
lavag
sputum
gram
stain
urinari
antigen
streptococcu
pneumonia
legionella
pneumophila
serolog
mycoplasma
pneumonia
legionella
pneumophila
chlamydia
pneumonia
detail
definit
cap
report
appendix
viral
cap
defin
pneumonia
case
least
one
viru
microbiolog
detect
respiratori
sampl
mix
infect
defin
cap
viru
detect
togeth
either
bacteria
fungi
coinfect
present
consid
viral
cap
studi
group
includ
analysi
follow
test
viru
group
includ
patient
underw
least
one
nasopharyng
oropharyng
swab
compar
patient
test
virus
b
swab
posit
group
includ
patient
test
viru
group
viru
microbiolog
detect
compar
patient
test
virus
neg
swab
c
influenza
cap
group
includ
patient
swab
posit
group
influenza
viru
isol
compar
patient
perform
viral
swab
neg
influenza
viru
frequenc
viral
nasopharyng
swab
test
calcul
consid
cap
patient
includ
glimp
dataset
preval
viral
cap
calcul
use
viral
isol
detect
viral
nasopharyng
swab
perform
first
h
hospit
admiss
categor
variabl
express
count
percentag
compar
group
use
chisquar
fisher
test
appropri
regress
analys
perform
compar
preval
determin
odd
ratio
confid
interv
ci
logist
regress
analys
perform
assess
relationship
viral
pneumonia
influenza
viru
pneumonia
demograph
therapeut
epidemiolog
clinic
variabl
chisquar
test
perform
compar
preval
countri
contin
statist
signific
defin
pvalu
statist
analys
perform
ibm
spss
statist
window
version
armonk
ny
ibm
crop
stata
colleg
station
tx
statacorp
lp
cap
patient
enrol
glimp
studi
test
virus
median
age
year
male
tabl
data
appendix
fig
total
patient
least
one
isol
viru
swab
posit
group
influenza
viru
isol
viral
cap
form
influenza
cap
group
fig
frequenc
nasal
swab
test
significantli
higher
asia
significantli
lower
africa
tabl
fig
spain
india
usa
itali
countri
highest
viral
swab
test
frequenc
weight
number
patient
enrol
fig
netherland
saudi
arabia
highest
test
frequenc
wherea
viral
swab
perform
portug
croatia
serbia
montenegro
bulgaria
nigeria
romania
fig
tabl
appendix
compar
test
virus
test
patient
significantli
younger
obes
often
posit
smoke
histori
test
group
respiratori
comorbid
asthma
obstruct
sleep
apnea
frequent
transplant
vaccin
frequent
sever
cap
admiss
tabl
swab
posit
group
virus
isol
preval
influenza
viru
rsv
rhinoviru
enteroviru
tabl
two
patient
two
virus
isol
time
therefor
total
number
patient
viral
cap
nineteen
patient
bacteri
coinfect
overal
preval
viral
cap
test
north
south
america
significantli
lower
preval
compar
particip
center
repres
contin
wherea
asian
countri
highest
preval
compar
particip
countri
north
america
significantli
lower
preval
influenza
viru
highest
preval
rhinoviru
enteroviru
tabl
compar
countri
india
itali
significantli
higher
preval
viral
cap
wherea
usa
argentina
significantli
lower
frequenc
tabl
appendix
patient
viral
cap
significantli
differ
rest
sampl
term
obes
respiratori
comorbid
vaccin
statu
cap
sever
tabl
independ
risk
factor
viral
cap
repres
obes
ci
pvalu
need
invas
mechan
ventil
hospit
admiss
ci
pvalu
tabl
appendix
focus
analysi
patient
influenza
signific
risk
factor
associ
influenza
cap
obes
influenza
group
significantli
differ
rest
popul
also
term
inhal
corticosteroid
use
vaccin
statu
hospit
prior
year
admiss
tabl
independ
risk
factor
occurr
influenza
cap
found
total
patient
cap
empir
treat
oseltamivir
among
test
nasal
viral
swab
among
viral
cap
fig
among
patient
tabl
secondari
analysi
intern
multicent
pointpreval
studi
show
patient
cap
low
rate
viral
test
low
preval
viral
pathogen
geograph
heterogen
regard
viral
assess
immunocompromis
state
prior
respiratori
comorbid
clinic
sever
cap
variabl
frequent
associ
viral
test
obes
need
invas
mechan
ventil
risk
factor
independ
associ
diagnosi
viral
cap
furthermor
one
third
cap
patient
suspect
viral
infect
underw
viral
test
empir
treat
oseltamivir
influenza
coverag
viral
cap
relev
caus
morbid
mortal
worldwid
preval
like
underestim
due
low
rate
inconsist
test
virus
gener
practic
present
specif
guidelin
avail
test
virus
hospit
patient
cap
howev
earli
diagnosi
treatment
viral
cap
caus
influenza
viru
known
notabl
clinic
implic
regard
sever
studi
show
preval
viral
cap
vari
howev
studi
limit
data
analys
test
patient
patient
enrol
systemat
test
viral
infect
present
studi
attempt
assess
reallif
scenario
patient
test
virus
preval
viral
cap
among
test
consist
recent
result
systemat
review
line
previou
report
result
show
influenza
viru
preval
pathogen
isol
account
posit
swab
consist
major
particip
countri
nevertheless
remark
differ
test
frequenc
occur
northern
southern
hemispher
fact
although
studi
period
includ
influenza
season
boreal
austral
area
spain
india
usa
itali
countri
highest
viral
swab
test
frequenc
weight
number
patient
enrol
specul
find
like
relat
epidemiolog
influenza
differ
local
standard
procedur
sever
factor
inconsist
consid
clinician
make
decis
regard
test
viral
pathogen
literatur
show
patient
like
test
base
sever
present
advanc
age
presenc
specif
symptom
find
imag
studi
presenc
inflammatori
marker
howev
patient
sign
symptom
specif
viral
infect
overlap
bacteri
cap
observ
may
support
previou
experi
influenza
pandem
show
higher
preval
sever
present
younger
obes
patient
compar
nonsever
obes
patient
evid
may
influenc
current
clinic
practic
rais
clinic
suspicion
patient
characterist
furthermor
previou
larg
studi
adopt
restrict
select
criteria
exclud
immunocompromis
patient
transplant
recipi
patient
previou
tuberculosi
may
lack
applic
real
life
clinic
circumst
current
studi
found
patient
like
undergo
test
virus
sever
cap
prior
respiratori
comorbid
obes
immunocompromis
due
malign
transplant
histori
previou
chemotherapi
group
recent
studi
etiolog
cap
immunocompromis
patient
found
preval
influenza
viru
similar
immunocompromis
immunocompet
patient
base
epidemiolog
background
immunocompromis
patient
cap
test
virus
avoid
underestim
risk
pathogen
found
obes
need
invas
mechan
ventil
two
risk
factor
associ
increas
incid
viral
cap
howev
obes
independ
risk
factor
associ
influenza
cap
consist
find
anim
model
suggest
role
leptin
dysregul
sever
diseas
higher
incid
sever
viral
cap
found
obes
patient
hand
sever
studi
show
sever
cap
need
icu
admitt
invas
ventil
associ
etiolog
thu
conclud
obes
independ
risk
factor
predispos
patient
influenza
infect
although
associ
obes
viral
cap
influenza
cap
could
overrepres
larg
proport
patient
influenza
viru
diagnos
cohort
atsidsa
guidelin
strongli
recommend
earli
treatment
oseltamivir
patient
influenza
systemat
review
carri
report
inconclus
data
efficaci
influenza
therapi
sever
prospect
retrospect
studi
show
treatment
oseltamivir
reduc
median
time
symptom
recoveri
incid
complic
associ
influenza
well
improv
outcom
patient
requir
admitt
icu
furthermor
recent
systemat
review
show
earli
administr
neuraminidas
inhibitor
oseltamivir
reduc
mortal
pneumonia
well
secondari
transmiss
present
studi
show
patient
admit
cap
empir
treat
within
h
half
patient
confirm
influenza
infect
start
therapi
oseltamivir
anoth
neuraminidas
inhibitor
moreov
sever
cap
admitt
appear
repres
reason
start
empir
coverag
oseltamivir
oseltamivir
administ
first
h
symptom
occurr
seem
prefer
treatment
influenza
despit
cost
increas
influenza
vaccin
coverag
could
reduc
burden
diseas
prescriptionrel
cost
viral
cap
recent
demonstr
major
caus
pneumonia
critic
ill
patient
requir
mechan
ventil
data
confirm
need
systemat
viral
test
patient
admit
cap
vast
global
heterogen
treatment
low
treatment
rate
explain
lack
specif
treatment
protocol
mani
institut
poor
adher
recommend
present
studi
sever
limit
firstli
base
studi
design
across
multipl
institut
investig
differ
polici
viral
test
center
select
use
kit
influenza
find
could
bias
underestim
role
play
virus
moreov
upper
airway
specimen
test
virus
decreas
diagnost
yield
mani
countri
patient
test
virus
major
case
associ
miss
prescript
oseltamivir
dispar
could
influenc
sever
factor
includ
lack
inadequ
standard
oper
procedur
local
guidelin
viral
test
poor
healthcar
resourc
delay
referr
hospit
symptom
initi
make
oseltamivir
administr
ineffect
studi
period
may
also
influenc
preval
viral
test
especi
influenza
northern
hemispher
furthermor
present
studi
evalu
outcom
patient
treat
oseltamivir
comparison
receiv
therapi
final
viral
identif
assess
local
protocol
per
studi
guidelin
fact
compar
particip
center
north
america
highest
preval
rhinovirusenteroviru
pneumonia
line
data
epic
studi
although
may
explain
differ
pcr
sensit
increas
diagnost
yield
specif
pathogen
acknowledg
pragmat
approach
studi
repres
import
limit
microbiolog
sampl
patient
manag
depend
local
standard
procedur
studi
protocol
howev
result
present
studi
show
everyday
clinic
practic
differ
reallif
set
thu
integr
data
random
clinic
trial
describ
weak
strength
current
manag
cap
patient
conclus
intern
scale
frequenc
test
viral
infect
patient
admit
cap
low
signific
variabl
countri
global
common
caus
viral
cap
influenza
viru
high
geograph
heterogen
obes
patient
like
undergo
test
import
develop
specif
guidelin
protocol
test
patient
virus
avoid
leav
decis
clinician
prefer
final
empir
treatment
oseltamivir
low
half
patient
confirm
influenza
infect
receiv
treatment
oseltamivir
evalu
viral
test
influenza
viru
need
base
poor
use
clinic
manag
project
fund
reli
sole
voluntari
site
investig
particip
result
present
studi
partial
present
may
american
thorac
societi
intern
confer
form
abstract
themat
poster
present
pleas
see
j
respir
crit
care
med
everi
patient
follow
characterist
risk
factor
includ
report
form
anthropometr
variabl
age
gender
height
weight
variabl
obes
underweight
calcul
b
respiratori
tract
comorbid
includ
presenc
activ
lung
cancer
asthma
bronchiectasi
chronic
aspir
chronic
obstruct
pulmonari
diseas
copd
forc
expiratori
volum
one
second
fev
predict
valu
accord
gender
age
ethnic
smoke
histori
currentform
smoker
interstiti
lung
diseas
obstruct
sleep
apnea
long
term
oxygen
therapi
lung
transplant
tracheostomi
c
cardiovascular
comorbid
includ
presenc
arrhythmia
coronari
arteri
diseas
heart
failur
arteri
hypertens
stroke
pharmacolog
therapi
includ
chronic
treatment
inhal
corticosteroid
proton
pump
inhibitor
statin
use
steroid
use
e
presenc
prosthet
materi
enter
tube
feed
haemodialysi
indwel
cathet
f
presenc
immunodepress
condit
within
month
hospit
admiss
activ
solid
tumour
acquir
immun
defici
syndrom
aplast
anaemia
asplenia
biolog
drug
use
chemotherapi
last
month
hematolog
malign
hiv
infect
neutropenia
g
presenc
comorbid
risk
factor
chronic
renal
failur
dementia
diabet
mellitu
liver
diseas
cirrhosi
malnutrit
alcohol
mental
ill
prosthet
materi
recurr
skin
infect
bedridden
contact
sport
healthcar
worker
homeless
inject
illicit
drug
live
crowd
condit
nurs
home
resid
worker
livestock
meat
industri
prior
mycobacteri
diseas
h
known
infect
colonis
within
month
hospit
admiss
follow
methicillin
resist
staphylococcu
aureu
mrsa
pseudomona
aeruginosa
extend
spectrum
betalactamas
produc
gramneg
bacilli
esbl
previou
healthcar
exposur
includ
antibiot
infus
home
last
month
emerg
room
admiss
last
month
hospit
last
month
intraven
antibiot
last
month
lower
respiratori
tract
infect
lrti
last
month
oral
antibiot
last
month
j
vaccin
statu
influenza
vaccin
current
past
influenza
season
pneumococc
conjug
vaccin
pcv
pneumococc
polysaccharid
vaccin
k
need
follow
within
h
hospit
admiss
invas
andor
noninvas
mechan
ventil
intens
care
unit
icu
high
depend
unitsemiintens
care
unit
admitt
vasopressor
inotrop
cap
communityacquir
pneumonia
cap
defin
evid
new
pulmonari
infiltr
thorac
imag
chest
radiograph
comput
tomographi
scan
ultrasound
first
h
hospit
least
one
follow
criteria
new
increas
cough
without
sputum
product
purul
respiratori
secret
fever
document
rectal
oral
temperatur
hypothermia
document
rectal
oral
temperatur
evid
system
inflamm
abnorm
white
blood
cell
count
leukocytosi
cell
per
ml
leucopenia
cell
per
ml
bandaemia
increas
creactiv
protein
procalcitonin
concentr
local
upper
limit
normal
sever
cap
defin
patient
requir
follow
icu
admiss
invas
noninvas
mechan
ventil
vasopressorsinotrop
first
h
hospit
admiss
sever
copd
defin
either
fev
predict
valu
long
term
oxygen
therapi
influenza
vaccin
consid
valid
done
prior
andor
current
influenza
season
previou
pneumococc
vaccin
includ
conjug
ie
immunodepress
defin
presenc
least
six
month
prior
hospit
admiss
follow
hematolog
malign
asplenia
aplast
anaemia
neutropenia
chronic
biolog
drug
use
chronic
steroid
treatment
hivaid
chemotherapi
immunosuppress
state
includ
congenitalgenet
immunosuppress
immunosuppress
therapi
due
hematologicalsolid
organ
transplant
lung
exclud
hematolog
malign
asplenia
aplast
anaemia
neutropenia
chronic
biolog
drug
chronic
steroid
treatment
hivaid
chemotherapi
least
six
month
hospit
admiss
anthropometr
clinic
characterist
patient
test
viral
swab
cap
communityacquir
pneumonia
mrsa
methicillin
resist
staphylococcu
aureu
copd
chronic
obstruct
pulmonari
diseas
forc
expiratori
volum
one
second
cad
coronari
arteri
diseas
esbl
extendedspectrum
betalactamas
lrti
lower
respiratori
tract
infect
statist
signific
frequenc
compar
continentscountri
bold
frequenc
oseltamivir
empir
coverag
contin
countri
